Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Assets: 2009-2025

Historic Non-Current Assets for Aytu Biopharma (AYTU) over the last 16 years, with Sep 2025 value amounting to $43.9 million.

  • Aytu Biopharma's Non-Current Assets fell 20.35% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year decrease of 20.35%. This contributed to the annual value of $45.0 million for FY2025, which is 19.94% down from last year.
  • Per Aytu Biopharma's latest filing, its Non-Current Assets stood at $43.9 million for Q3 2025, which was down 2.49% from $45.0 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Non-Current Assets registered a high of $171.5 million during Q1 2021, and its lowest value of $43.9 million during Q3 2025.
  • Over the past 3 years, Aytu Biopharma's median Non-Current Assets value was $56.2 million (recorded in 2024), while the average stood at $56.3 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 106.03% in 2021, then plummeted by 51.57% in 2022.
  • Over the past 5 years, Aytu Biopharma's Non-Current Assets (Quarterly) stood at $136.3 million in 2021, then slumped by 48.03% to $70.8 million in 2022, then decreased by 15.46% to $59.9 million in 2023, then declined by 11.20% to $53.2 million in 2024, then fell by 20.35% to $43.9 million in 2025.
  • Its Non-Current Assets was $43.9 million in Q3 2025, compared to $45.0 million in Q2 2025 and $51.7 million in Q1 2025.